

### Friday, 22nd November

**10:00 – 16:30**    **Chronic Malignancies Working Party Scientific Business Meeting**  
*Open for everybody*

### Saturday, 23<sup>rd</sup> November

**08:30 – 08:45**    **Welcome and overview of the Working Party**  
*Chairs: Joanna Drozd-Sokołowska (PL) & Donal McLornan (UK)*

**08:45 – 10:25**    **Session I: Allo-HCT for MDS in 2024**  
*Chairs: Joanna Drozd-Sokołowska (PL) & Kavita Raj (UK)*

08:45 – 09:00    MDS classification in 2024: ICC versus WHO and the allo-HCT decision  
09:00 – 09:15    The IPSS-Molecular: Using IPSS-M to guide allo-HCT decisions for MDS  
09:15 – 09:20    Discussion and Q&A  
09:20 – 09:35    Germline predisposition traits: considerations in allo-HCT for MDS  
09:35 – 09:50    Transplant for *TP53* mutated MDS: how to approach in 2024  
09:50 – 09:55    Discussion and Q&A  
09:55 – 10:10    Integrating Novel drugs into the MDS allo-HCT algorithm  
10:10 – 10:20    Trainee Case Presentation  
10:20 – 10:25    Discussion and Q&A

Joanna Drozd-Sokołowska (PL)  
Grzegorz Basak (PL)

Carmelo Gurnari (IT)  
Kavita Raj (UK)

Krzysztof Mądry (PL)

**10:25 – 11:00**    *Coffee Break*

**11:00 – 11:30**    **Industry Symposium + Q&A**

**11:30 – 13:10**    **Session II: Improving Allo-HCT Outcomes for MPN**  
*Chair: Juan Carlos Hernandez Boluda (SP) & Donal McLornan (UK)*

11:30 – 11:45    Optimization of GVHD prophylaxis strategies in MF allo-HCT  
11:45 – 12:00    Role of  $\alpha\beta$ T cell depletion in allo-HCT for MF  
12:00 – 12:05    Discussion and Q&A  
12:05 – 12:20    Haploidentical Transplantation for MF  
12:20 – 12:35    Management of poor graft function and relapse in MF allo-HCT  
12:35 – 12:40    Discussion and Q&A  
12:40 – 12:55    Allo-HCT for atypical MPN: EBMT position  
12:55 – 13:15    How best to approach Donor Lymphocyte Infusions in MF allo-HCT:  
Case-based illustrative cases  
A novel CAR-T cell therapy for Calreticulin mutated myelofibrosis  
13:15 – 13:20    Discussion and Q&A

Juan Carlos H. Boluda (SP)  
Moniek de Witte (NL)

Tomasz Czerw (PL)  
Giorgia Battipaglia (IT)

Nicola Polverelli (IT)

Nico Gagelmann (DE)  
Alex Rampotas (UK)

**13:20 – 14:15**    *Lunch Break*

## Preliminary Programme

Warsaw, Poland  
22-23 November 2024

**14:15 - 14:45**     **Industry Symposium + Q&A**

**14:45 - 15:20**     **Session III: Improving Patient and Caregiver Satisfaction Treatment Decisions for MDS and MPN**

*Chair: Fernando Duarte (BR)*

14:45 - 15:00     Can we incorporate patient preferences in clinical trial design for novel agents in MDS and MPN?

Esra Gülderen (TR)

15:00 - 15:15     Psychological Burdens for patients and caregivers in the allo-HCT decision process

15:15 - 15:20     Discussion and Q&A

**15:20 - 16:45**     **Session IV: Optimizing Outcomes for MDS/MPN overlap syndromes**

*Chair: Katja Sockel (DE) & Francesco Onida (IT)*

15:20 - 15:35     How to manage cases of MDS/MPN- unclassifiable/NOS

Donal McLornan (UK)

15:35 - 15:50     Role of Novel agents in the management of CMML: an update

Katja Sockel (DE)

15:50 - 16:05     Improving outcomes for allo-HCT in CMML: the Brazilian experience

Fernando Duarte (BR)

16:05 - 16:20     Improving outcomes for allo-HCT in CMML: the EBMT position

Francesco Onida (IT)

16:20 - 16:30     Trainee Case Presentation

16:30 - 16:40     Discussion and Q&A

16:40 - 16:45     Closing remarks

Joanna Drozd-Sokołowska (PL)